Vanguard Group Inc Vyne Therapeutics Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.12 - $4.91 $134 - $5,489	1,118 Added 0.07%	1,650,607 $247,000
Q3 2022 Nov 14, 2022	SELL	$0.24 - $4.27 $36,249 - $644,945	-151,041 Reduced 8.39%	1,649,489 $368,000
Q2 2022 Aug 12, 2022	BUY	$0.37 - $0.71 $118,623 - $227,628	320,604 Added 21.66%	1,800,530 $700,000
Q1 2022 May 13, 2022	SELL	$0.5 - $1.15 $383,152 - $881,250	-766,305 Reduced 34.12%	1,479,926 $962,000
Q4 2021 Feb 14, 2022	SELL	$0.91 - $1.5 $173,082 - $285,301	-190,201 Reduced 7.81%	2,246,231 $2.29 Million
Q2 2021 Aug 13, 2021	BUY	$3.24 - $6.92 $7.89 Million - $16.9 Million	2,436,432 New	2,436,432 $8.55 Million

36.5K

Ticker VYNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,005,600
Market Cap $184M
Description
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, whi...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.